tradingkey.logo
tradingkey.logo
Search

Oruka Therapeutics Inc

ORKA
Add to Watchlist
96.510USD
-1.350-1.38%
Close 07-31 16:00ETQuotes delayed by 15 min
4.84BMarket Cap
LossP/E TTM

More Details of Oruka Therapeutics Inc Company

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Oruka Therapeutics Inc Info

Ticker SymbolORKA
Company nameOruka Therapeutics Inc
IPO dateJul 21, 2000
CEOKlein (Lawrence Otto)
Number of employees28
Security typeOrdinary Share
Fiscal year-endJul 21
Address855 Oak Grove Ave.
CityMENLO PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94025
Phone16506067910
Websitehttps://orukatx.com/
Ticker SymbolORKA
IPO dateJul 21, 2000
CEOKlein (Lawrence Otto)

Company Executives of Oruka Therapeutics Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
445.26K
-0.39%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
236.38K
--
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Independent Director
Independent Director
108.32K
+21.31%
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Independent Director
Independent Director
38.74K
-90.34%
Mr. Arjun Agarwal
Mr. Arjun Agarwal
Senior Vice President - Finance, Treasurer
Senior Vice President - Finance, Treasurer
12.67K
--
Dr. Joana Goncalves, M.D.
Dr. Joana Goncalves, M.D.
Chief Medical Officer
Chief Medical Officer
1.96K
--
Mr. Paul T. Quinlan
Mr. Paul T. Quinlan
General Counsel, Secretary
General Counsel, Secretary
565.00
-129.73%
Ms. Kristine M. Ball
Ms. Kristine M. Ball
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence Otto Klein, Ph.D.
Dr. Lawrence Otto Klein, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
445.26K
-0.39%
Ms. Laura Sandler
Ms. Laura Sandler
Chief Operating Officer
Chief Operating Officer
236.38K
--
Dr. Cameron Turtle, Ph.D.
Dr. Cameron Turtle, Ph.D.
Independent Director
Independent Director
108.32K
+21.31%
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Independent Director
Independent Director
38.74K
-90.34%
Mr. Arjun Agarwal
Mr. Arjun Agarwal
Senior Vice President - Finance, Treasurer
Senior Vice President - Finance, Treasurer
12.67K
--
Dr. Joana Goncalves, M.D.
Dr. Joana Goncalves, M.D.
Chief Medical Officer
Chief Medical Officer
1.96K
--

FAQs

Who are the top five shareholders of Oruka Therapeutics Inc?

The top five shareholders of Oruka Therapeutics Inc are: Dr. Lawrence Otto Klein, Ph.D.

How many institutions hold shares of Oruka Therapeutics Inc (ORKA)?

As of 2026Q1, 266 institutions hold shares of Oruka Therapeutics Inc, with a combined market value of approximately 56.79M, accounting for 98.54% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 6980689.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.